JP2019507608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507608A5 JP2019507608A5 JP2018563769A JP2018563769A JP2019507608A5 JP 2019507608 A5 JP2019507608 A5 JP 2019507608A5 JP 2018563769 A JP2018563769 A JP 2018563769A JP 2018563769 A JP2018563769 A JP 2018563769A JP 2019507608 A5 JP2019507608 A5 JP 2019507608A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- gene
- allele
- cancer cell
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299674P | 2016-02-25 | 2016-02-25 | |
| US62/299,674 | 2016-02-25 | ||
| US201662425027P | 2016-11-21 | 2016-11-21 | |
| US62/425,027 | 2016-11-21 | ||
| PCT/US2017/019757 WO2017147600A1 (en) | 2016-02-25 | 2017-02-27 | Whole-cell cancer vaccines and methods for selection thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507608A JP2019507608A (ja) | 2019-03-22 |
| JP2019507608A5 true JP2019507608A5 (enExample) | 2020-04-02 |
| JP6901505B2 JP6901505B2 (ja) | 2021-07-14 |
Family
ID=59685619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563769A Active JP6901505B2 (ja) | 2016-02-25 | 2017-02-27 | 全細胞がんワクチンおよびその選択のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11559574B2 (enExample) |
| EP (1) | EP3419657A4 (enExample) |
| JP (1) | JP6901505B2 (enExample) |
| CN (1) | CN109069603A (enExample) |
| AU (3) | AU2017224232B2 (enExample) |
| CA (2) | CA3300406A1 (enExample) |
| IL (1) | IL261354A (enExample) |
| NZ (1) | NZ745327A (enExample) |
| WO (1) | WO2017147600A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069603A (zh) | 2016-02-25 | 2018-12-21 | 布里卡尔治疗公司 | 全细胞癌症疫苗及其选择方法 |
| WO2019112942A1 (en) * | 2017-12-04 | 2019-06-13 | Heat Biologics, Inc. | Production of cell-based vaccines |
| EP3727467A4 (en) * | 2017-12-22 | 2021-12-01 | Centivax, Inc. | MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE |
| CN108175853A (zh) * | 2018-01-24 | 2018-06-19 | 上海赛群生物科技有限公司 | 一种肿瘤细胞疫苗及其制备方法 |
| CN108486038B (zh) * | 2018-03-21 | 2021-08-27 | 中国人民解放军第四军医大学 | 一种构建脂肪干细胞膜片的方法及应用 |
| WO2020132595A1 (en) * | 2018-12-21 | 2020-06-25 | The Regents Of The University Of California | Il-10-containing vaccines and uses thereof |
| JP2023504659A (ja) | 2019-12-03 | 2023-02-06 | ニューボーゲン，インコーポレイティド | 腫瘍細胞ワクチン |
| CN110938630B (zh) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | 人b3gnt5基因的用途及相关产品 |
| WO2023092053A1 (en) * | 2021-11-18 | 2023-05-25 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based cancer treatments |
| IL315361A (en) | 2022-03-03 | 2024-11-01 | Briacell Therapeutics Corp | Cancer vaccines and methods of use thereof |
| CN115433734B (zh) * | 2022-06-01 | 2025-03-04 | 北京奇糖科技有限公司 | 核酸片段及其在制备肿瘤疫苗中的应用 |
| CN117990593A (zh) * | 2024-01-31 | 2024-05-07 | 南昌铭硕生科生物工程有限公司 | 一种流式多因子分析系统及其分析方法 |
| WO2025171109A1 (en) | 2024-02-07 | 2025-08-14 | Briacell Therapeutics Corp. | Cancer vaccines expressing post-translational modified antigens and methods of use thereof |
| CN118207320A (zh) * | 2024-04-28 | 2024-06-18 | 复旦大学附属中山医院 | Hla-c*04:01基因的新用途及检测试剂盒 |
| CN118207319A (zh) * | 2024-04-28 | 2024-06-18 | 复旦大学附属中山医院 | Hla-a*03:04基因的新用途及检测试剂盒 |
| WO2026068517A1 (en) * | 2024-09-24 | 2026-04-02 | Universiteit Gent | Cancer immunotherapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
| US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
| EP1165776A1 (en) * | 1999-02-22 | 2002-01-02 | Ludwig Institute For Cancer Research | TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| WO2006081629A1 (en) | 2005-02-04 | 2006-08-10 | Stem Cell Australia Pty Ltd | Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy. |
| WO2006135454A1 (en) * | 2005-06-08 | 2006-12-21 | Saint Vincent Medical Center, A California Corporation | Novel cancer cell lines and uses thereof |
| US20080020386A1 (en) | 2006-03-29 | 2008-01-24 | Medigen Biotechnology Corporation | Methods and apparatus for genotyping |
| US7807186B2 (en) * | 2007-01-17 | 2010-10-05 | University Of Maryland, Baltimore County | Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines |
| WO2010045573A2 (en) | 2008-10-17 | 2010-04-22 | University Of Miami | Tumor vaccine |
| WO2012083240A2 (en) * | 2010-12-16 | 2012-06-21 | Dana-Farber Cancer Institute, Inc. | Oligonucleotide array for tissue typing |
| AU2012257377B2 (en) | 2011-05-17 | 2017-09-07 | Hadasit Medical Research Services And Development Ltd. | Allogeneic tumor cell vaccination |
| CN109069603A (zh) | 2016-02-25 | 2018-12-21 | 布里卡尔治疗公司 | 全细胞癌症疫苗及其选择方法 |
-
2017
- 2017-02-27 CN CN201780023982.8A patent/CN109069603A/zh active Pending
- 2017-02-27 CA CA3300406A patent/CA3300406A1/en active Pending
- 2017-02-27 JP JP2018563769A patent/JP6901505B2/ja active Active
- 2017-02-27 AU AU2017224232A patent/AU2017224232B2/en active Active
- 2017-02-27 CA CA3015080A patent/CA3015080A1/en active Pending
- 2017-02-27 NZ NZ745327A patent/NZ745327A/en unknown
- 2017-02-27 WO PCT/US2017/019757 patent/WO2017147600A1/en not_active Ceased
- 2017-02-27 EP EP17757429.0A patent/EP3419657A4/en active Pending
-
2018
- 2018-08-23 IL IL261354A patent/IL261354A/en unknown
- 2018-08-23 US US16/110,317 patent/US11559574B2/en active Active
-
2022
- 2022-10-28 AU AU2022259857A patent/AU2022259857B2/en active Active
- 2022-12-09 US US18/078,351 patent/US20230277640A1/en active Pending
-
2025
- 2025-07-03 AU AU2025205094A patent/AU2025205094A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tykodi et al. | Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens | |
| Leung | Use of NK cell activity in cure by transplant | |
| Zilberberg et al. | Strategies for the identification of T cell–recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation | |
| Kera et al. | Significant associations of HLA‐B* 5101 and B* 5108, and lack of association of class II alleles with Behçet’s disease in Italian patients | |
| EP3539553B1 (en) | Activation and expansion of nkg2c+ nk cells | |
| Bernstein et al. | Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells | |
| Malard et al. | Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution’s three decade experience | |
| CN110997903A (zh) | 用于癌症治疗的t细胞的活化方法 | |
| JP2020532956A5 (enExample) | ||
| Chou et al. | Immunomodulatory effects of Saccharomyces cerevisiae fermentation product supplementation on immune gene expression and lymphocyte distribution in immune organs in broilers | |
| JP2019507608A (ja) | 全細胞がんワクチンおよびその選択のための方法 | |
| Luo et al. | The impact of inflationary cytomegalovirus‐specific memory T cells on anti‐tumour immune responses in patients with cancer | |
| JP2021530501A5 (enExample) | ||
| JP2024051157A5 (enExample) | ||
| Chen et al. | HLA class II polymorphisms associated with the physiologic characteristics defined by traditional Chinese medicine: linking modern genetics with an ancient medicine | |
| Eisenblätter et al. | Validation and functional follow‐up of cervical cancer risk variants at the HLA locus | |
| JP2021507924A5 (enExample) | ||
| Park et al. | KIR alloreactivity based on the receptor–ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study | |
| Garziera et al. | Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond | |
| Nowak et al. | Epstein‐Barr virus infections are strongly dependent on activating and inhibitory KIR‐HLA pairs after T‐cell replate unrelated hematopoietic stem cell transplantation, the principles, and method of pairing analysis | |
| Lio et al. | TNFα, IFNγ and IL-10 gene polymorphisms in a sample of Sicilian patients with coeliac disease | |
| Fousteri et al. | Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure | |
| Kayser et al. | Severe ankylosing spondylitis and diffuse systemic sclerosis: case report of a genetic trap | |
| Kornblit et al. | Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation | |
| Emtestam et al. | Multiple basal cell carcinomas: no association with HLA‐DRB, HLA‐DQAI or HLA‐DQBI in Swedish patients |